Aligned with its continuous successful launches of innovative brands and differentiated generics, Algorithm has launched in October 2011 in the Lebanese market, Ziorel® and Ziorel Plus®, being the first generics to Irbesartan and Irbesartan+Hydrochlorothiazide.

Ziorel® & Ziorel Plus® are indicated for the treatment of Hypertension, as well as the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with Type 2 Diabetes and Hypertension.

Ziorel® & Ziorel Plus® (30’s film coated tablets) are respectively available in the below dosages

• 150mg & 300mg
• 150/12.5mg & 300/12.5mg

Ziorel® & Ziorel Plus® are The Smart Move Towards Optimal Hypertension Management, being also bioequivalent and reimbursed by local National Social Security Fund (NSSF).